IL6 and retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache syndrome: As DF-003 treatment (5 mg/kg) reduced Il6 upregulation in our ROSAH model mice, this offers further support for its potential clinical utility in ROSAH patients.